StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) income statement

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.67−0.01 (-0.01%)

Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma plc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
59.6%
Net margin
32.1%
Return on equity, FY2025
–

Financial strength

Current ratio
2.80
Debt to equity
–
Debt to assets
45.2%
Cash to current liabilities
128.7%

Valuation

P/E ratio
39.0
Price to sales
15.57
Price to book
–
Dividend yield
–

See a number that looks wrong?